Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands
An erratum to this article was published (Cardiovasc Diabetol, 15 May 2025 ↗)
Authors' conclusion
By reducing the risk of CKD progression and CV events, finerenone saves costs to society while gaining QALYs in patients with T2D and advanced CKD in the Netherlands.
Study context
- Population
- Patients with advanced chronic kidney disease (CKD) associated with T2D in the Netherlands
- Exposure
- Finerenone added to standard of care (SoC) vs SoC alone
- Outcome
- Incremental costs, utilities and incremental cost-effectiveness ratio (ICER)
- Follow-up
- Lifetime
Methodological detailsMarkov cohort model, lifetime time horizon, Dutch societal perspective, sensitivity and scenario analyses
- Markov cohort model
- Lifetime time horizon
- Dutch societal perspective
- Sensitivity and scenario analyses
Main finding
As reported in the abstract
Cost-effectiveness
Quality-adjusted life years (QALYs) gained
0.20 QALYs
Cost-effectiveness
Decrease in total lifetime costs per patient
€6136
lower costs with finerenone; dominant treatment option
Observational data: associations, not effects.
Further findings
| Outcome | Estimate |
|---|---|
| Time free of CV events and renal replacement therapy · lifetimeFinerenone + SoC vs SoC | extension of time free of CV events 0.30 life years |
| Time free of CV events and renal replacement therapy · lifetimeFinerenone + SoC vs SoC | extension of time free of renal replacement therapy 0.31 life years |
Probabilistic sensitivity analysis
- Probability finerenone + SoC dominant
- 83%
- Probability cost-effective at willingness-to-pay threshold of €20,000
- 93%
Original publication
Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands. Cardiovasc Diabetol. Published 28 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →